์ •์ฃผ ์ง€์งˆ์œ ์ œ / Intravenous lipid emulsion

์ •์˜

Intravenous lipid emulsion์€ ์ง€์šฉ์„ฑ ๋…์„ฑ ๋ฌผ์งˆ์„ ํ˜ˆ๊ด€ ๋‚ด๋กœ ๋Œ์–ด๋“ค์—ฌ ์กฐ์ง ๋…์„ฑ์„ ์ค„์ด๋Š” ๋ชฉ์ ์œผ๋กœ ์“ฐ์ด๋Š” ํ•ด๋… ๋ณด์กฐ ์น˜๋ฃŒ์ด๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

์น˜๋ฃŒ

โš ๏ธ Paper-only ๊ฒ€์ฆ ์ „๊นŒ์ง€ ์ด ์ ˆ์˜ ILE ์šฉ๋Ÿ‰ยท์ง€์†์‹œ๊ฐ„ยทECMO ์ „ํ™˜ claim์€ raw-only ์˜ˆ์‹œ๋กœ ์ทจ๊ธ‰ํ•œ๋‹ค. Local anesthetic systemic toxicity(LAST)์—์„œ 20% lipid emulsion ์‚ฌ์šฉ ๋ฐฉํ–ฅ์€ ASRA ๋“ฑ ์ฒดํฌ๋ฆฌ์ŠคํŠธ/๊ฐ€์ด๋“œ๋ผ์ธ์œผ๋กœ source-bound ๊ฐ€๋Šฅํ•˜์ง€๋งŒ, 1.5 mL/kg bolus, 0.25 mL/kg/min ์ง€์†, ์ตœ๋Œ€ ์šฉ๋Ÿ‰, ๋ฐ˜๋ณต bolus, ์ข…๋ฃŒ ๊ธฐ์ค€์€ ์›๋ฌธ ๊ธฐ์ค€ ํ™•์ธ ์ „ ํ™•์ • ๊ถŒ๊ณ ๋กœ ์“ฐ์ง€ ์•Š๋Š”๋‹ค. ์ž๋ฃŒ์˜ 24์‹œ๊ฐ„ continuous ํ›„์—๋„ ํ•„์š”ํ•˜๋ฉด ECMO ํ‘œํ˜„์€ ๊ณผ๋„ํ•˜๊ฒŒ ๋‹จ์ˆœํ™”๋  ์ˆ˜ ์žˆ์–ด, refractory cardiovascular collapse์—์„œ๋Š” ACLS/LAST ์น˜๋ฃŒ์™€ ๋ณ‘ํ–‰ํ•˜์—ฌ ์กฐ๊ธฐ ECMO ๊ฐ€๋Šฅ์„ฑ์„ ์ „๋ฌธํŒ€๊ณผ ๋…ผ์˜ํ•˜๋Š” ๋ฐฉํ–ฅ์œผ๋กœ๋งŒ ๋ณด์กดํ•œ๋‹ค.

๋ชจ๋‹ˆํ„ฐ๋ง

์ถœ์ฒ˜

๐ŸŒฑ ์ถœ์ฒ˜ raw


๋ณธ ๋ฌธ์„œ๋Š” ํ•™์Šตยท์ฐธ๊ณ ์šฉ์ด๋ฉฐ ์‹ค์ œ ์ง„๋ฃŒ ๊ฒฐ์ •์€ ์ž„์ƒ์˜์˜ ํŒ๋‹จ์ž…๋‹ˆ๋‹ค.